Ms. Wendy Zamor
Matrix Laboratories Inc.
76 South Orange Ave., Suite 301
South Orange, NJ 07079

RE: The tariff classification of Letrozole (CAS-112809-51-5) in bulk form, from India

Dear Ms. Zamor:

In your letter dated August 13, 2009, you requested a tariff classification ruling.

The subject product, Letrozole, is a non-steroidal aromatase inhibitor. It is indicated for the adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.

The applicable subheading for the Letrozole in bulk form will be 2933.99.7500, Harmonized Tariff Schedule of the United States (HTSUS), which provides for “Heterocyclic compounds with nitrogen hetero-atom(s) only: Other: Other: Aromatic or modified aromatic: Other: Drugs: Other.” Pursuant to General Note 13, HTSUS, the rate of duty will be free.

Duty rates are provided for your convenience and are subject to change. The text of the most recent HTSUS and the accompanying duty rates are provided on World Wide Web at

This merchandise may be subject to the Federal Food, Drug, and Cosmetic Act and/or The Public Health Security and Bioterrorism Preparedness and Response Act of 2002 (The Bioterrorism Act), which are administered by the U.S. Food and Drug Administration (FDA). Information on the Federal Food, Drug, and Cosmetic Act, as well as The Bioterrorism Act, can be obtained by calling the FDA at 1-888-463-6332, or by visiting their website at

This ruling is being issued under the provisions of Part 177 of the Customs Regulations (19 C.F.R. 177).

A copy of the ruling or the control number indicated above should be provided with the entry documents filed at the time this merchandise is imported. If you have any questions regarding the ruling, contact National Import Specialist Harvey Kuperstein at (646) 733-3033.


Robert B. Swierupski
National Commodity Specialist Division